You're describing a compound known as **10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone**. This is a complex organic molecule, and here's why it might be important for research:
**Structure and Properties:**
* **Acridinone core:** The base structure of the molecule is acridinone, a heterocyclic compound with a nitrogen atom in a three-ringed system. Acridinones have shown biological activity, especially in relation to DNA interactions.
* **Substituents:** The molecule has a bulky side chain attached at position 10. This side chain contains:
* **Dibutylamino group:** This group provides a basic character and could potentially interact with biological targets.
* **Hydroxypropyl group:** The hydroxyl group (OH) adds polarity to the molecule and might be involved in hydrogen bonding interactions.
**Potential Research Applications:**
Given its structure, this compound might be of interest for research in areas like:
* **Anti-cancer agents:** Acridinones have been explored for their potential as anti-cancer agents due to their ability to interact with DNA. The specific substituents on this molecule could influence its activity against specific cancer cells.
* **Antibacterial agents:** Some acridinones exhibit antimicrobial properties, and the side chain in this compound could modify its activity against various bacteria.
* **Photodynamic therapy:** Acridines can be used as photosensitizers in photodynamic therapy (PDT) to kill cancer cells. The specific substituents on this molecule could impact its ability to absorb light and generate reactive oxygen species.
* **Other biological activities:** The combination of the acridinone core and the side chain substituents could potentially lead to various other biological activities, such as anti-inflammatory, antiviral, or antioxidant effects.
**Important Considerations:**
* **Toxicity:** Any potential use of this compound in biological systems would require extensive toxicological studies to assess its safety.
* **Synthesis and characterization:** The synthesis of this compound might be challenging, and its properties need to be carefully characterized before any further research.
* **Target identification:** Identifying the specific biological targets for this molecule is crucial to understand its mechanism of action and potential therapeutic applications.
**Conclusion:**
10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone is a complex molecule with potential for research in various biological fields. However, further studies are necessary to fully understand its properties and potential applications.
ID Source | ID |
---|---|
PubMed CID | 3724061 |
CHEMBL ID | 1508993 |
CHEBI ID | 117023 |
Synonym |
---|
MLS001030052-02 |
MLS001030052 |
10-(3-dibutylamino-2-hydroxy-propyl)-10h-acridin-9-one |
smr000427277 |
CHEBI:117023 |
AKOS005461420 |
10-[3-(dibutylamino)-2-hydroxypropyl]acridin-9-one |
STK528661 |
10-[3-(dibutylamino)-2-hydroxypropyl]acridin-9(10h)-one |
HMS2778K17 |
CHEMBL1508993 |
10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone |
Q27203647 |
Class | Description |
---|---|
acridines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 39.8107 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 75.1137 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 11.5821 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 44.6684 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
geminin | Homo sapiens (human) | Potency | 12.8321 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |